Reactions 1132 - 16 Dec 2006

■ The US FDA has informed healthcare professionalsthat Baxter has revised the Warnings section of thelabelling for heparin sodium injection to highlight thepotential of delayed onset of heparin-inducedthrombocytopenia (HIT), and to highlight that HIT maydevelop into heparin-induced thrombocytopenia andthrombosis (HITT). Furthermore, the agency statesthat thrombotic events could be the initial presentationof HITT, which can happen up to several weeks afterheparin discontinuation, and that patients should beevaluated for HIT and HITT if they present withthrombocytopenia or thrombosis after heparindiscontinuation.FDA. Heparin sodium injection. Internet Document : [1 page], 8 Dec 2006.Available from: URL: http://www.fda.gov 801013809

1

Reactions 16 Dec 2006 No. 11320114-9954/10/1132-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved